These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 8916313)

  • 61. The benefit of induction chemotherapy in patients age > or = 75 years.
    Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
    Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
    Saşmaz I; Tanyeli A; Bayram I; Antmen B; Yilmaz L; Küçükosmanoğlu O; Kilinç Y
    Turk J Pediatr; 2004; 46(1):32-7. PubMed ID: 15074372
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
    Watanabe A; Kuriyama H; Kiyota T
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 65. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
    Holowiecki J; Rudzka E; Jarczok K; Holowiecka B; Krawczyk M; Duraj M; Japa J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(6):792-7. PubMed ID: 6200390
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
    Helg C; Chapuis B; Grob JP; Pugin P
    Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
    Paciucci PA; Dutcher JP; Cuttner J; Strauman JJ; Wiernik PH; Holland JF
    Leukemia; 1987 Jul; 1(7):565-7. PubMed ID: 3478540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
    Tsurumi H; Miura T; Yamada T; Sawada M; Nakamura N; Tomoda T; Takahashi T; Oyama M; Moriwaki H; Muto Y
    Rinsho Ketsueki; 1995 Jul; 36(7):657-64. PubMed ID: 7563593
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
    Lee DH; Chung NG; Cho B; Kim HK; Kang HJ; Shin HY; Ahn HS; Yoo KH; Sung KW; Koo HH; Kook H; Hwang TJ; Im HJ; Seo JJ; Park HJ
    J Korean Med Sci; 2010 Jan; 25(1):9-15. PubMed ID: 20052341
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?
    Bassan R; Barbui T
    Haematologica; 1995; 80(1):82-90. PubMed ID: 7758997
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [An intensification therapy of adults acute leukemia].
    Kawamura S; Kawarada R; Tsushima Y; Sawada Y; Yoshida Y; Chiba Y; Yamaya T; Kawatsu S; Aizawa M; Segawa M
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):83-7. PubMed ID: 2643396
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 74. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical evaluation of cases of remission induction failure in acute myelogenous leukemia].
    Saito M; Ino T; Shigemura H; Shimizu S; Matsui T; Ono Y; Nakamura K; Okamoto M; Takada T; Imura H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):554-60. PubMed ID: 3859249
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
    Takubo T; Kubota Y; Tanaka T; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):283-9. PubMed ID: 6576729
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract]   [Full Text] [Related]  

  • 79. Prognostic factors of acute non lymphoblastic leukemia in children and adults. Results from two multicentric trials (705 patients).
    Castaigne S; Chevret S; Lepage E; Guilhot F; Fenaux P; Bordessoule D; Tilly H; Auzanneau G; Tertian G; Guy H
    Nouv Rev Fr Hematol (1978); 1990; 32(5):297-300. PubMed ID: 2099400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
    Harousseau JL; Reiffers J; Hurteloup P; Milpied N; Guy H; Rigal-Huguet F; Facon T; Dufour P; Ifrah N
    J Clin Oncol; 1989 Jan; 7(1):45-9. PubMed ID: 2642539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.